Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK

C. E. Gollins; A. Shah; K. Sinha; S. Khan; N. Paul; B. Meeajun; R. A. Abbott; C. Blasdale; H. Cooper; C. A. Harwood; F. Ismail; J. T. Lear; L. Mackintosh; S. McCormack; C. M. Perrett; C. M. Proby; A. Durack; R. Patalay; R. N. Matin

doi:10.1111/bjd.18982

Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK

C. E. Gollins (Lead / Corresponding author)
, A. Shah
, K. Sinha
, S. Khan
, N. Paul
, B. Meeajun
, R. A. Abbott
, C. Blasdale
, H. Cooper
, C. A. Harwood
, F. Ismail
, J. T. Lear
, L. Mackintosh
, S. McCormack
, C. M. Perrett
, C. M. Proby
, A. Durack
, R. Patalay
, R. N. Matin

Research output: Contribution to journal › Letter › peer-review

5 Citations (Scopus)

310 Downloads (Pure)

Abstract

Keratinocyte cancers (KC) are the commonest malignancies in the UK population, with rates increasing annually. Nicotinamide (vitamin B3) has recently been reported to reduce the incidence of KC in high-risk patients. It is a precursor of nicotinamide adenine dinucleotide (NAD+) which replenishes cellular energy levels and enhances efficient repair of ultraviolet light (UV) induced DNA damage within keratinocytes.

Original language	English
Pages (from-to)	394-396
Number of pages	3
Journal	British Journal of Dermatology
Volume	183
Issue number	2
Early online date	2 Mar 2020
DOIs	https://doi.org/10.1111/bjd.18982
Publication status	Published - 1 Aug 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Dermatology

Access to Document

10.1111/bjd.18982

Author Accepted ManuscriptAccepted author manuscript, 1.76 MB

Cite this

Gollins, C. E., Shah, A., Sinha, K., Khan, S., Paul, N., Meeajun, B., Abbott, R. A., Blasdale, C., Cooper, H., Harwood, C. A., Ismail, F., Lear, J. T., Mackintosh, L., McCormack, S., Perrett, C. M., Proby, C. M., Durack, A., Patalay, R., & Matin, R. N. (2020). Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK. British Journal of Dermatology, 183(2), 394-396. https://doi.org/10.1111/bjd.18982

@article{2523c722b655403782f6a423de287161,

title = "Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK",

abstract = "Keratinocyte cancers (KC) are the commonest malignancies in the UK population, with rates increasing annually. Nicotinamide (vitamin B3) has recently been reported to reduce the incidence of KC in high-risk patients. It is a precursor of nicotinamide adenine dinucleotide (NAD+) which replenishes cellular energy levels and enhances efficient repair of ultraviolet light (UV) induced DNA damage within keratinocytes.",

author = "Gollins, \{C. E.\} and A. Shah and K. Sinha and S. Khan and N. Paul and B. Meeajun and Abbott, \{R. A.\} and C. Blasdale and H. Cooper and Harwood, \{C. A.\} and F. Ismail and Lear, \{J. T.\} and L. Mackintosh and S. McCormack and Perrett, \{C. M.\} and Proby, \{C. M.\} and A. Durack and R. Patalay and Matin, \{R. N.\}",

year = "2020",

month = aug,

day = "1",

doi = "10.1111/bjd.18982",

language = "English",

volume = "183",

pages = "394--396",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "2",

}

Gollins, CE, Shah, A, Sinha, K, Khan, S, Paul, N, Meeajun, B, Abbott, RA, Blasdale, C, Cooper, H, Harwood, CA, Ismail, F, Lear, JT, Mackintosh, L, McCormack, S, Perrett, CM, Proby, CM, Durack, A, Patalay, R & Matin, RN 2020, 'Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK', British Journal of Dermatology, vol. 183, no. 2, pp. 394-396. https://doi.org/10.1111/bjd.18982

TY - JOUR

T1 - Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK

AU - Gollins, C. E.

AU - Shah, A.

AU - Sinha, K.

AU - Khan, S.

AU - Paul, N.

AU - Meeajun, B.

AU - Abbott, R. A.

AU - Blasdale, C.

AU - Cooper, H.

AU - Harwood, C. A.

AU - Ismail, F.

AU - Lear, J. T.

AU - Mackintosh, L.

AU - McCormack, S.

AU - Perrett, C. M.

AU - Proby, C. M.

AU - Durack, A.

AU - Patalay, R.

AU - Matin, R. N.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Keratinocyte cancers (KC) are the commonest malignancies in the UK population, with rates increasing annually. Nicotinamide (vitamin B3) has recently been reported to reduce the incidence of KC in high-risk patients. It is a precursor of nicotinamide adenine dinucleotide (NAD+) which replenishes cellular energy levels and enhances efficient repair of ultraviolet light (UV) induced DNA damage within keratinocytes.

AB - Keratinocyte cancers (KC) are the commonest malignancies in the UK population, with rates increasing annually. Nicotinamide (vitamin B3) has recently been reported to reduce the incidence of KC in high-risk patients. It is a precursor of nicotinamide adenine dinucleotide (NAD+) which replenishes cellular energy levels and enhances efficient repair of ultraviolet light (UV) induced DNA damage within keratinocytes.

UR - https://www.scopus.com/pages/publications/85083180133

U2 - 10.1111/bjd.18982

DO - 10.1111/bjd.18982

M3 - Letter

C2 - 32119116

SN - 0007-0963

VL - 183

SP - 394

EP - 396

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 2

ER -

Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this